High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma

https://prabadinews.com/

weborders@prabadincorp.com

+1 (786)-332-3938

$High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma$

Health

By AdminPrabadin - 10 months ago

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

administrator

Related Articles